

Mar. 13. 2008 12:36PM
01/25/2008 14:23

Farsight Patents (650)-679-9596
6507809030

FARSIGHT/HIGH TECHNI

No. 0030 P. 10/11

PAGE 07/08

RECEIVED
CENTRAL FAX CENTER

MAR 13 2008

RECEIVED
CENTRAL FAX CENTER

JAN 25 2008

Intarcia Dkt No. ALE 054.11

USSN: 09/976,228

PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
<i>Jay R. Fabian</i>	25 January 2008
Signature	Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: KLEINER, Lothar, et al.	Confirmation No.: 9517
Serial No.: 09/976,228	Art Unit: 1616
Filing Date: 12 October 2001	Examiner: Brown, C.A.
Title: RATE CONTROLLING MEMBRANES FOR CONTROLLED DRUG DELIVERY DEVICES	

**AUTHORIZATION TO CHARGE OR CREDIT DEPOSIT ACCOUNT AND
BLANKET PETITION FOR EXTENSION OF TIME**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

If a paper is untimely filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative, the Commissioner is hereby petitioned under 37 CFR § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Commissioner is hereby requested to charge any fee required under 37 CFR § 1.17(a)-(d) to Deposit Account No. 504212 (please reference docket number ALE 054.11). This, however, is not authorization to pay the Issue Fee.

RECEIVED
CENTRAL FAX CENTER

PAGE 08/08

JAN 25 2008

Intarcia Dkt No. ALE 054.11
USSN: 09/976,228
PATENT

If a paper is concurrently or subsequently filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative and a fee under 37 CFR §§ 1.16-1.17 is required to effect any amendment, petition or other action requested in said paper, the Commissioner is hereby requested to charge any deficiency in said fee, or credit any overpayment of said fee, to Deposit Account No. 504212. This, however, is not authorization to pay the Issue Fee.

Respectfully submitted,

By:

Gary R. Fabian

Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

Dated: 25 January 2008

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608
Phone: (510) 652-2600
Fax: (510) 652-2657